Company
Gilead Sciences Inc
NASDAQ:GILD
Gilead Sciences Inc is a biopharmaceutical company. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. Gilead Sciences Inc offers products in HIV, Onocolgy, Liver Disease, Vekulaery and Other.
86 stories
Maxcyte: At the forefront of cell therapy revolution; exits 2020 in rude health
"With a resilient business model we have every reason to remain highly optimistic for the future"
Gilead says remdesivir drug unaffected by new strains of coronavirus
Remdesivir does not target the spike proteins of the coronavirus that are altered in new variants of the coronavirus
WHO advises against use of Gilead’s remdesivir for COVID-19 treatment
The agency said there is currently no evidence that it improves survival or the need for ventilation
Gilead Sciences says remdesivir plays important role for COVID-19 patients treatment
The drug made US$873mln sales in the third quarter, helping group revenues to rise to US$6.6bn
Gilead Sciences slams WHO after trial shows remdesivir not effective in avoiding COVID-19 death
The Solidarity study proved that the candidate had little to no effect in helping patients’ chances of survival
Anger as US snaps up supplies of Gilead coronavirus treatment Remdesivir
Developed economies have to go through the US pharma giant, which holds the patent.
Gilead slaps multi-thousand-dollar price tag on coronavirus treatment remdesivir
The pharma giant intends to charge developed countries US$2,340 for a five-day treatment, while other parts of the world can access generic versions
Gilead Sciences' remdesivir shows improvement in coronavirus patients with moderate pneumonia
Patients taking a 5-day course of treatment recover faster compared to the standard of care
Gilead Sciences, Roche to study remdesivir/Actemra combination in coronavirus patients
Gilead’s remdesivir is currently approved as emergency treatment for coronavirus while Roche has been studying the effectiveness of arthritis treatment Actemra
Gilead Sciences' remdesivir to be available for selected coronavirus patients in the UK
The drug is being used as emergency treatment in Japan and the US, while generic versions will be distributed in 127 countries
Gilead Sciences' remdesivir to be distributed in 127 countries
The deals were signed with Cipla, Ferozsons Laboratories, Hetero Labs, Jubilant Lifesciences and Mylan
Gilead Sciences' remdesivir receives US emergency approval for coronavirus treatment
The temporary authorisation follows trials that confirmed the drug allows for faster recovery but safety and efficacy have not been proven yet
Gilead Sciences' remdesivir could get US emergency approval for coronavirus treatment
The drug has not been approved anywhere yet and has not been demonstrated to be safe or effective in coronavirus cases.
Gilead Sciences posts positive data on coronavirus treatment trial
Patients receiving a ten-day course of remdesivir achieved similar improvement compared with those being treated for five days
Gilead Sciences says studies for coronavirus treatment still inconclusive after unsuccessful trial in China
The World Health Organization accidentally posted data from trials in China showing that the drug, considered very promising, was not successful
Hardware & electrical equipment
Coronavirus research: who got the priority label from the government
Here are some of the companies involved in projects that have been fast-tracked by the UK authorities
Coronavirus: What’s happening in the labs of pharma companies worldwide
A list of the major pharma players looking for solutions to tackle the pandemic
Gilead Sciences gives hope for coronavirus treatment with latest data
Remdesivir was originally designated as a treatment for Ebola
S&P/ASX 200 futures down 1.2% heading into the open, US markets fall overnight
The S&P 500 closed down 2.93% and the Nasdaq Composite closed down 0.27%.
Gilead gets a boost as its Ebola drug gets repurposed to treat the coronavirus
It is working with Chinese officials to set up a study of the drug’s effectiveness against the virus
Pharma stocks head south as Trump forces them to display drug prices in TV ads
“Drug companies have to come clean about their prices in TV ads. If drug companies are ashamed of those prices – lower them!”
Viking Therapeutics shares pop after rival Gilead's liver drug trial falls short
Viking stands to benefit after Gilead’s drug selonsertib did not meet its primary endpoint in a Phase 3 trial
Late Movers: Walt Disney rallies after reporting 1Q results that beat estimates
Also moving were Electronic Arts and General Motors, which reports Wednesday
Small-Cap Snapshot: Pier 1 Imports slumps after saying it's exploring strategic options
MannKind, Agenus and BlackBerry are also seeing trading action
Agenus partners with Gilead Sciences to develop five immuno-oncology therapies
Agenus will receive a $120 million upfront payment and a $30 million equity investment from Gilead
Archive
Proactive news snapshot: Sirius Minerals, MaxCyte, Arix Bioscience...
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Two Shields and Bushveld wave the flag for African mineral assets
A look at the day's winners and sinners, including Dignity, Online Blockchain, Restaurant Group, TomCo Energy, Johnston Press, GYG, Anglo African Agriculture and Carr's Group
MaxCyte inks research agreement with Gilead subsidiary Kite Pharma
The AIM-listed bioscience firm said under the agreement Kite would use its Flow Electroporation Technology platform to enable non-viral cell engineering
A sixth sense for biotech helps Arix Bioscience turn risk into profit as portfolio value nearly doubles
Analysts at Stifel say the venture capital firm is entering its first extended period of sustained news flow with shares trading at about 45% discount to their £2.53 price target
EARLY MOVERS: Apple set to create big buzz as it reveals new iPhones; Micron Technology shares down after Goldman note
Also in focus in pre-market deals is Bausch Health Cos Inc, formerly Valeant, and Gilead Sciences
Large-cap biotech companies seem poised to outperform in 2Q, says Oppenheimer analyst
'We remain cautiously bullish on the sector, albeit with a stock-picking approach,' writes Hartaj Singh
Gilead Sciences’s 1Q earnings miss gets shares, but Oppenheimer analysts say not to worry
Sales of the California biotech's cancer drug Yescarta was double what analysts expected
Gilead Sciences misses on 1Q earnings and revenue, maintains outlook
The biopharma company recently announced a partnership with Alphabet start-up Verily Life Science
Gilead Sciences strikes partnership with Alphabet's Verily
Forbes reported Gilead would pay Verily US$90mln to probe immune cells
Gilead Sciences and Sangamo Therapeutics to collaborate on engineered cell therapies for cancer treatment
Kite will use Sangamo's zine finger nuclease technology platform to develop the next-generation therapies for autologous and allogeneic use in treating different cancers
GlaxoSmithKline winning over City number crunchers
Is the market being too negative about the prospects for the HIV franchise and generic competition to its best-selling asthma treatment, Advair?
Abzena a play on the biologics revolution, says City broker
The subsector in which Abezena is active in (monoclonal antibody and conjugated monoclonal antibodies) could expand to US$180bn, Peel Hunt’s research suggests
GSK sues US rival Gilead Sciences for alleged HIV drug patent infringement
GSK’s one pill, once daily treatment was approved back in November, while Gilead’s drug got the green light from the US FDA on Wednesday
GSK warns 2018 earnings hinge on generic competition to its blockbuster Advair inhaler
If a generic competitor comes to market this summer as expected, GSK said earnings will fall by between 0-3%, while if a competitor isn’t forthcoming, earnings will rise by 4-7%
Snap, Gilead Sciences, Walt Disney Co and more - AFTER HOURS
Proactive takes a look t what happened after the bell in New York
Gilead Sciences, Celgene Corp, Cytokinetics and more - PRE-MARKET
Proactive takes a look at what's piquing investor interest before the bell in New York
GSK steals a march on rivals as its two drug, one pill HIV treatment gets green light from FDA
Juluca – as the treatment is known – is made by GSK’s majority-controlled ViiV Healthcare and is the first such drug to be approved by US authorities
Gilead Sciences shares bolstered after FDA approval validates Kite Pharma merger
This is a huge win for the pharma group, and validates its US$12bn acquisition this summer of Kite Pharma Inc
Verizon Communications, Gilead Sciences, Alcoa Corp, PayPal Holdings - PRE-MARKET
We take a look at what's moving the needle in New York, ahead of the bell
Wall Street shares mixed going into close
US shares started Monday mixed after futures had pointed lower
United Therapeutics opens 10% higher as GlaxoSmithKline is named as a potential bidder for the group
Sources are cited as saying the bidding could go as high as US$200 a share, valuing the business at US$8.7bn
Facebook, Gilead Sciences and Discover Financial Services and more
We are looking at all the movers and shakers after the bell
Merck and Gilead among drug stocks buoyed by Trump’s healthcare plans
The Republicans are looking to repeal Obamacare as well as trying to ease regulatory pressures in the industry
US stocks end higher after stronger payrolls point to rate hike
US stocks ended the week at the top of their Friday session range after stronger-than-expected non-farm payrolls confirmed a Federal Reserve rate hike on March 15
Pharmaxis enters 2017 cashed up as shares strengthen
Pharmaxis is becoming a more enticing target for drug acquisition and partnerships.
US stocks recover from losses as analysts focus on surprise gasoline supply drop
US stocks recovered from intraday losses to end higher on Wednesday after analysts focused on a fall in gasoline inventories rather than a spike in oil supplies
Pharmaxis on track for multi-million euro milestone payment
The commencement of the trial will trigger a milestone payment.
AbbVie's revenue miss clouds strong Humira US sales
AbbVie Inc shares were lower on Friday after the pharma reported quarterly adjusted revenue that missed analysts' estimates as weaker-than-expected sales of its hepatitis C treatment and cancer therapy overshadowed strong US demand for its
Immuron watches several high-value NASH related deals
Microbiome company Immuron (ASX:IMC) is witnessing a series of high-value licensing merger & acquisition (LM&A) deals related to NASH (non-alcoholic steatohepatitis) assets.
Gilead order to pay US$2.54bn in royalties after losing patent battle
It is the biggest patent-infringement verdict in US history and, of course, the loser is appealing against it.
US stocks drop on election jitters
US stocks closed lower in a broad fall on Tuesday, led by dividend-paying sectors, as traders eyed a safer haven-inspired drop in Treasury bond yields as well as headlines on the looming presidential election a week away
Gilead Sciences to advance NASH treatment into phase III trials
Gilead announced phase II results for its selonsertib NASH treatment, which was tested in combination with simtuzumab, an antibody that contains Abzena’s technology
Gilead ends trial of ulcerative colitis treatment notes Abzena
The termination affects only one indication out of five currently being trialled by Gilead
Abzena's drug-boosting animal antibodies
Proactive Investors looks at Abzena, a biotech firm that engineers antibodies from animals in order to boost the effectiveness of cancer-fighting drugs.
Abzena's expanded offering plays well with customers
"Our increased capabilities and capacity are already resulting in an excellent response from customers,” said chief executive John Burt.
Gilead gets European Commission approval to market HIV drug
Truvada is first antiretroviral medicine licensed in Europe for pre-exposure prevention method
Medivation faces buyers’ scrum - report
A scrum to acquire US cancer drug company Medivation was emerging on Wednesday after reports that Merck, Pfizer and Gilead Sciences were among at least five pharmaceutical companies expressing an interest
Investments and investor services
Papers: Priceline CEO resigns following employee relationship investigation
Also featured: Amazon.com, Medivation, Gilead Sciences and Tobacco
Gilead's third TAF-Based HIV therapy approved by FDA
Gilead Sciences says the US Food and Drug Administration has approved Descovy, a fixed-dose combination for the treatment of HIV and "first new HIV treatment backbone approved in a decade"
Stocks find forward gear at last
The oil price (WTI) had its best day in seven years
Gilead Sciences can market HIV-1 drug in Europe
Gilead Sciences can now market its tablet for HIV-1 infection in Europe
Trending - Skechers, Gilead Sciences, Anavex Life Sciences, plus the top risers
A mention on Mad Money lights a fire under Skechers and Gilead Sciences.
Wall Street to open higher before Fed release; Citrix jumps, Twitter tumbles
U.S. stock index futures rose today on hopes that Beijing could stem the rout in its markets and ahead of a statement from the U.S. Federal Reserve that could give clues regarding the timing of a rate hike. S&P 500 futures rose 0.2 perc
AstraZeneca "to miss out on US drug deal" - sources
Receptos is said to have rebuffed $200 per share bid approach from AstraZeneca